Drug intelligence / Profile preview

AIG13

Development stage: Preclinical
Lead developer: AIGEN Sciences
Modality: Small Molecules

Overview

AIG13 is a small molecule inhibitor of Poly(ADP-ribose) glycohydrolase (PARG) currently in preclinical development by AIGEN Sciences. PARG is an enzyme responsible for the degradation of poly(ADP-ribose) (PAR) polymers, which are synthesized by PARP enzymes in response to DNA damage. By inhibiting PARG, AIG13 leads to the accumulation of PAR, which disrupts DNA repair processes and induces synthetic lethality in cancers with specific DNA repair deficiencies, such as BRCA1-deficient solid tumors. The program is currently in the lead optimization stage of preclinical development.

Targets

PARG (Poly(ADP-ribose) glycohydrolase)

Beyond the preview

Go deeper on AIG13.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AIG13.

Explore the full profile